Biomerica reported fiscal 2025 results with revenue essentially flat at $5.3 million and a narrowed operating loss of $5.1...

FDA has approved Eisai and Biogen’s Leqembi iqlik, a once-weekly 360 mg subcutaneous autoinjector for maintenance dosing after 18...

Boehringer Ingelheim has secured accelerated approval in China for HERNEXEOS (zongertinib) as monotherapy for adults with unresectable, locally advanced,...

Genentech has entered an exclusive collaboration and license agreement with OMass Therapeutics for a preclinical oral small molecule program...

Charm Therapeutics has closed an oversubscribed $80 million Series B co-led by New Enterprise Associates and SR One to...

Pharming Group has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The rare disease-focused biopharma, active...

China’s National Medical Products Administration has granted accelerated, conditional approval to Boehringer Ingelheim’s Hernexeos (zongertinib) as monotherapy for adults...

Minovia Therapeutics has secured a $350,000 research grant from Countdown for a Cure to advance blood-based mitochondrial biomarkers, while...

Biomerica reported fiscal 2025 results with net sales essentially flat at $5.3 million and a 19% year-over-year improvement in...

Santhera Pharmaceuticals has signed a five-year exclusive agreement with Ikris Pharma Network to distribute Agamree (vamorolone) for the treatment...